New Treatment For Resistant Gout Enters a New Clinical Trial
March 14th, 2007Drug manufacturer Savient has announced that the drug Puricase is entering a new phase of clinical trials. This is great news for people whose Gout does not respond to standard drug treatments or those who are unable to take currently available medicines.
Given that pork products have long been acknowledged to hasten Gout attacks, it is ironic that Puricase is derived from pigs — specifically porcine urate oxidase.
Another positive aspect of the beginning of these new phase 3 trials is the news that 100% of the patients who successfully completed the first two phases have opted to continue treatment.
